ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-OR36

Kidney and Cancer Outcomes with Standard vs. Kidney Protective Chemotherapy Regimens for First-Line Treatment of Metastatic Urothelial Carcinoma

Session Information

Category: Onco-Nephrology

  • 1500 Onco-Nephrology


  • Côté, Gabrielle, University of Toronto, Toronto, Ontario, Canada
  • Alqaisi, Husam A., University of Toronto, Toronto, Ontario, Canada
  • Sridhar, Srikala Sujata, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada
  • Kitchlu, Abhijat, Toronto General Hospital, Toronto, Ontario, Canada

Cisplatin-based combination chemotherapy regimen is the optimal initial treatment for metastatic urothelial carcinoma, but kidney function eligibility and nephrotoxicity are treatment-limiting for many patients. For patients unfit to receive cisplatin, other options include alternative administration schedules (e.g. split dose cisplatin), carboplatin-based regimens and non-platinum regimens. The aims of this study were to compare cancer outcomes and incidence of acute kidney injury (AKI) during treatment among 3 regimens of chemotherapy.


We conducted a single-center retrospective study of patients receiving first-line chemotherapy for metastatic urothelial carcinoma (2005-2019). We compared standard gemcitabine-cisplatin (gem-cis) to: 1) gemcitabine-cisplatin split dose regimen (split) with cisplatin divided over day 1 and 8; and 2) combination of gemcitabine-carboplatin or single-agent gemcitabine (gem/gem-carbo). We used Fine and Gray hazard models accounting for baseline covariates and competing risk of death.


We identified 183 patients (98 gem-cis, 32 split and 53 gem/gem-carbo). Median age was 67 years-old (IQR: 61-73) and 76% were male. Median baseline eGFR was 78 mL/min/1.73m2 (IQR: 66-91) in gem-cis, 64 (48-77) in split, and 45 (33-57) in gem/gem-carbo. Patients receiving split and gem/gem-carbo were older, had worse performance status, and hypertension was more frequent. Split and gem/gem-carbo regimens were associated with higher mortality and progressive disease relative to gem-cis when adjusted for age, baseline eGFR, ECOG, hypertension and diabetes with hazard ratio (HR) of 1.56 (95%CI: 1.04-2.34; p=0.03) and 2.02 (95%CI: 1.36-3.01; p<0.01) respectively. Median time to progressive disease was 242 (IQR: 137-444), 182 (122-279) and 131 (68-257) days in gem-cis, split and gem/gem-carbo groups. There was no significant association between regimen type and AKI with HR of 1.32 (95%CI: 0.62-2.81; p=0.47) and 0.98 (95%CI:0.46-2.09; p=0.96) for split and gem/gem-carbo groups versus gem-cis.


Kidney protective chemotherapy regimens were associated with increased disease progression and mortality, without a significant difference in AKI. Alternative kidney protective strategies are needed for patients with CKD and urothelial cancer.